22 August 2024: Aker BioMarine ASA ("AKBM") has mandated Arctic Securities, DNB
Markets and Nordea as joint lead managers to arrange a series of fixed income
investor meetings commencing Friday 23 August 2024. A new NOK denominated 3-year
senior secured floating rate bond issue may follow, subject to inter alia market
conditions. As previously announced, AKBM has entered into an agreement to sell
the Feed Ingredients business. The proceeds from the sale and the potential bond
issue will be employed towards refinancing existing debt, distributing an
extraordinary dividend and to fund general corporate purposes.

The Investor Presentation used in connection with the fixed income meetings is
attached. 


For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  
 
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.